Home/Pipeline/Copper 175 mm² IUD

Copper 175 mm² IUD

Contraception

Phase 3Active

Key Facts

Indication

Contraception

Phase

Phase 3

Status

Active

Company

Sebela Pharmaceuticals

About Sebela Pharmaceuticals

Sebela Pharmaceuticals is a private, commercial-stage biopharmaceutical company founded in 2014 and headquartered in Braintree, Massachusetts. The company operates with a dual focus: maintaining a leading position in the gastroenterology market through its affiliate Braintree and driving innovation in women's health via its Sebela Women's Health division. Its near-term value drivers include the FDA review of tegoprazan for GERD and the recent licensing of its hormone-free IUD, MIUDELLA®, to Organon, while its pipeline suggests a commitment to sustained growth in its core therapeutic areas.

View full company profile

Therapeutic Areas

Gastroenterology Women's Health

Other Contraception Drugs

Drug	Company	Phase	Status
Drosperinone + Ethinyl Estradiol Tablets	BDR Pharmaceuticals	Commercial	Approved
Gen II FemCap Commercialization	FemCap	Approved	Active
Eucontra	Hera Health Solutions	Filed	Active
3Daughters IUD	3Daughters	Pre-clinical	Active
Twirla® (levonorgestrel/ethinyl estradiol)	Agile Therapeutics	Approved	Commercial
SiRx‑Contraception	SiCare Bio	Discovery	Active
Novel Oral Contraceptive Combinations	RPG Life Sciences	Formulation Development	Active
AYA™ (etonogestrel) contraceptive vaginal system	Organon	Filed	Under FDA Review